FeaturedMedia Release
Race signs agreement with NSF Health Sciences to file IND
Race Oncology is pleased to announce it has executed an agreement with Washington D.C - based advisory firm, NSF Health Sciences, to facilitate its IND1 filing in the US for leukaemia drug Bisantrene.
- Posted by: Race Oncology
FeaturedMedia Release
Bisantrene receives ‘Rare Paediatric Disease’ designation from FDA
Race Oncology is pleased to announce that it has received a letter from the FDA advising that Bisantrene has been granted Rare Paediatric Disease (RPD) designation for the treatment of childhood
- Posted by: Race Oncology
FeaturedMedia Release
Chart: Long-term survival case report of patients treated with Bisantrene Combination Therapy
The chart below details the long-term survival case report of two paediatric relapsed or refractory Acute Myeloid Leukemia patients treated with Bisantrene Combination Therapy.
- Posted by: Race Oncology
FeaturedMedia Release
Bisantrene granted unlicensed medicine approval in UK
Race Oncology is pleased to announce that approval has been received from the Medicines and Healthcare products Regulatory Agency (MHRA) for importation and distribution of Bisantrene as an
- Posted by: Race Oncology
FeaturedMedia Release
French doctors hail Race’s Bisantrene in new case report
Race Oncology is pleased to announce a case report describing the successful use of Bisantrene to treat childhood relapsed/refractory AML. The report will be published at a forthcoming oncology
- Posted by: Race Oncology
Featured
Proactive Investor interviews John Cullity
Race Oncology Non-Executive Director Dr. John Cullity speaks with Proactive Investors about the company's cancer chemotherapy drug, Bisantrene.
- Posted by: Race Oncology
Featured
New director upbeat about Race Oncology’s growth prospects
New Race non-executive director Dr John Cullity has used his first interview to highlight the company's growth potential.
- Posted by: Race Oncology